mestranol

[mes´trah-nol]

a synthetic estrogen used in combination with a progestational agent as an oral contraceptive.

mestranol

(mĕs′trə-nôl′, -nōl′, -nŏl′)

A synthetic estrogen, C₂₁H₂₆O₂, used in combination with a progestin in oral contraceptives.

mestranol

An oestrogen drug, used in combination with a PROGESTOGEN as an oral contraceptive or as a hormone replacement therapy for post-menopausal women. A brand names of a combination with the progestogen NORETHISTERONE is Norinyl-1.

Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005

Mentioned in

References in periodicals archive

Proestrogens, such as mestranol, are known to require metabolic transformation to exert estrogenic effects (Schmider et al.

Evaluation and Optimization of Pharmacokinetic Models for in Vitro to in Vivo Extrapolation of Estrogenic Activity for Environmental Chemicals

To help improve the reliability of the test, 100 [micro]g of mestranol is also given daily to stabilize estrogen levels during the testing interval.

Big step forward and downward: an OC with 10 [micro]g of estrogen: Lo Loestrin Fe delivers an ultra-low close of ethinyl estradiol--a novel and noteworthy option when you're considering an estrogen-progestin contraceptive

In vitro and in vivo genotoxicity evaluation of hormonal drugs V, mestranol. Mutation Research, 322: 173-183.

Anticlastogenic effects of ascorbic acid against the genotoxic damage induced by norethynodrel

Of these, 4-nonylphenol (linear) was inactive in all 3 ToxCast[TM] in vitro binding assays (but active in 10 of 11 of the remaining agonist-mode assays), 4-dodecylphenol was inactive in 2 of 3 assays (bovine and mouse), and mestranol was inactive in only 1 (mouse) of 3 ToxCast[TM] assays (see Figure 4).

Evaluation of OASIS QSAR models using ToxCast[TM] in vitro estrogen and androgen receptor binding data and application in an integrated endocrine screening approach

All combination OCs contain either EE or mestranol. However, a variety of progestins have come into use.

OCs, breakthrough bleeding, and patients' need to know: managing expectations is as important as adjusting formulations

[7] The use of oral contraceptives containing less than 100 [microgram] of either ethinyl estradiol or mestranol has approximately one third the risk of thromboembolism that using those products containing 100 [microgram] or more of the estrogen component has.

Oral contraceptives in the immediate postpartum period

Preparation of 9-alpha, 11-xi-tritiated 17-alpha-ethynylestradiol, mestranol, estradiol-alpha-17-beta, and norethindrone.

The short-chain fatty acid methoxyacetic acid disrupts endogenous estrogen receptor-[alpha]-mediated signaling